Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 735 results for adult social

  1. Is an integrated care system effective at promoting successful progress for people with complex psychosis to a more independent setting?

    system to support transitions. The integrated system was a team of health and social care practitioners and informal carers for each...

    Research recommendation
    Published
    26 October 2020

  2. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

    NICE guideline
    Published
    9 June 2022
    View recommendations

    Sections for NG219

  3. Managing glioma: supportive care clinics for low-grade glioma:- Does a dedicated supportive care clinic in addition to standard care improve outcomes for people with low-grade gliomas?

    complex healthcare needs across multiple physical, cognitive, emotional and social domains. This is often from the initial diagnosis...

    Research recommendation
    Published
    11 December 2018

  4. What is the comparative effectiveness and cost effectiveness of exercise referral schemes compared with other interventions that aim to help people to become more physically active? Relative effectiveness and cost effectiveness should be compared in controlled trials.

    referral schemes that seek to improve the health of sedentary or inactive adults with an existing health condition – or other factors...

    Research recommendation
    Published
    9 June 2015

  5. What factors encourage under-represented groups to participate in and complete an exercise referral scheme? What factors prevent these groups from participating? Under-represented groups include: people from black and minority ethnic groups, people with disabilities and those from lower socioeconomic groups.

    referral schemes that seek to improve the health of sedentary or inactive adults with an existing health condition – or other factors...

    Research recommendation
    Published
    9 June 2015

  6. What factors encourage uptake of, and adherence to, an exercise referral scheme? Factors to consider include: design, content and delivery; referral mechanisms; choice of activity; qualifications and cost of instructors. Also identify any barriers preventing participation and factors that encourage it.

    referral schemes that seek to improve the health of sedentary or inactive adults with an existing health condition – or other factors...

    Research recommendation
    Published
    9 June 2015

  7. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    17 April 2019
    View recommendations

    Sections for TA575

  8. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing...

    Research recommendation
    Published
    9 June 2015

  9. Holistic assessment in the community:- What is the clinical and cost effectiveness of a community holistic assessment and intervention for people living with high levels of multimorbidity?

    However, the studies were conducted outside the UK and were not aimed at all adults living with multimorbidity. The guideline committee...

    Research recommendation
    Published
    18 October 2016

  10. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

    HealthTech guidance
    Published
    19 December 2024
    View recommendations

    Sections for HTG735

  11. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  12. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

    Technology appraisal guidance
    Published
    13 March 2024
    View recommendations

    Sections for TA955

  13. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

    Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA410

  14. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

    Technology appraisal guidance
    Published
    20 December 2017
    View recommendations

    Sections for TA495

  15. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    12 December 2018
    View recommendations

    Sections for TA550